What question did this study set out to answer?

To determine whether pravastatin, simvastatin, and atorvastatin directly alter platelet reactivity and modify platelet sensitivity to acetylsalicylic acid (ASA) in vitro.

February 14, 2012European Journal of Clinical InvestigationOpen Access

Pravastatin and simvastatin improves acetylsalicylic acid‐mediated in vitro blood platelet inhibition

View Full Paper

Ask AI

Bookmark

Why the study?

Do pravastatin, simvastatin, and atorvastatin modulate in vitro platelet reactivity and sensitivity to ASA in blood from healthy volunteers?

Population

Blood platelets originating from healthy volunteers (in vitro)

Comparison

Incubation with pravastatin, simvastatin… vs ASA alone or baseline (no statin)

Design

Preclinical

Authors

BLBogusława LuzakMedical University of Lodz JRJoanna RywaniakUniversity of Łódź LSLidia StańczykMedical University of Lodz

Discussion

Member takes

Implication

No immediate clinical implications for statin selection with ASA; leaves open differential pleiotropic platelet effects in vivo.

Key Points

To determine whether pravastatin, simvastatin, and atorvastatin directly alter platelet reactivity and modify platelet sensitivity to acetylsalicylic acid (ASA) in vitro.
Incubated whole blood and isolated platelets from healthy volunteers with pravastatin, simvastatin, atorvastatin, and/or 50 μM ASA.
Measured collagen- and ADP-induced platelet aggregation, surface expression of CD36, PAC-1, and CD62, and thromboxane generation.
Simvastatin and pravastatin significantly decreased CD36 surface expression on platelets, whereas atorvastatin had no effect on baseline platelet aggregation or inhibition.
In the presence of 50 μM ASA, simvastatin and pravastatin significantly reduced PAC-1 expression (30% reduction for simvastatin, P < 0.01; 15% reduction for pravastatin, P < 0.01), platelet aggregation (20% reduction for both, P < 0.01), and thromboxane generation (35% reduction for simvastatin, P < 0.001; 30% reduction for pravastatin, P < 0.001) compared to ASA alone.

Structured PICO

Do pravastatin, simvastatin, and atorvastatin modulate in vitro platelet reactivity and sensitivity to ASA in blood from healthy volunteers?

Population

Blood platelets originating from healthy volunteers (in vitro)

Intervention

Incubation with pravastatin, simvastatin, atorvastatin and/or acetylsalicylic acid (ASA)

Comparator

ASA alone or baseline (no statin)

Outcome

Collagen- or ADP-induced platelet aggregation, CD36, PAC-1 and CD62 expression on platelet surface, and thromboxane generationsurrogate

Simvastatin and pravastatin, but not atorvastatin, enhance ASA-mediated platelet inhibition in vitro, suggesting potential pleiotropic effects on platelet function.

Cite This Study

Luzak et al. (2012) studied this question.

synapsesocial.com/papers/6a6f5cfe87f921057127191b https://doi.org/10.1111/j.1365-2362.2012.02661.x

Topics

Statin therapy Dual antiplatelet therapy PCSK9 inhibitors

View Full Paper

Ask AI

Bookmark

Pravastatin and simvastatin improves acetylsalicylic acid‐mediated in vitro blood platelet inhibition

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Pravastatin and simvastatin improves acetylsalicylic acid‐mediated in vitro blood platelet inhibition

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider